Eevia Health

Eevia Health is progressing in its product development with plans to start clinical studies for MaxBIOME™ and ProRENIS™, targeting gut and kidney health, respectively. These products are aimed at the growing global nutraceutical market, with a goal to launch by 2026. Eevia has signed Letters of Intent with two established nutraceutical companies, indicating a mutual interest in exploring commercial agreements and market strategies after clinical trials. Erik Eide, Eevia's Commercial Director, highlighted the strong interest from these potential partners, which supports the commercial potential of Eevia's products. Eevia Health, founded in 2017, produces bioactive compounds from sustainably harvested plant materials, primarily from Finnish and Swedish forests. The company is committed to environmentally friendly production and operates a facility in Finland. Eevia's shares are listed on the Spotlight Stock Market in Sweden. For more information, contact CEO Stein Ulve or visit their website.

Eevia Health Plc received an accelerated order for their organic elderberry extract, FENO-SAMBUCUS™ 7 ORGANIC, from a U.S. nutraceutical brand due to higher-than-expected demand. The extract, known for supporting immune and general wellness, is ready for immediate delivery, benefiting Eevia's cash flow. Eevia, founded in 2017, produces 100% organically certified plant extracts from Finnish and Swedish forests, focusing on gut and related health. The company operates a sustainable production facility in Finland and is listed on the Spotlight Stock Market in Sweden.

Several major U.S. companies are urgently seeking alternative sources for plant-based ingredients due to high import tariffs on Chinese products. Eevia Health has received multiple requests from U.S. buyers looking for European-origin supplies, as tariffs are lower. Although the U.S. tariffs are seen as temporary, their uncertain duration has led to increased purchasing and procurement strategies. Eevia sees potential short-term sales opportunities, especially in low-concentrate extracts and powders, and is assessing logistics and raw material availability to handle larger orders. This situation could enhance Eevia’s position as a reliable European supplier and underscores the importance of regional supply chain resilience. Eevia Health, founded in 2017, produces organic plant extracts from Finnish and Swedish forests, focusing on health-related products. The company operates a green-chemistry facility in Finland and is listed on the Spotlight Stock Market in Sweden.

Denna vecka mottog Eevia Health Plc nya försäljningsorder på totalt 50 000 euro. Dessa inkluderar 28 000 euro för Feno-Chaga™ Organic SKUs, 11 000 euro för Feno-Myrtillus® Organic SKUs och 11 000 euro för andra högkoncentrerade polyfenolextrakt. Alla beställda produkter finns i lager, vilket möjliggör omedelbar leverans och förbättrar kassaflödet. Orderna visar på en fortsatt efterfrågetillväxt för Eevias premiumorganiska bioaktiva ingredienser på strategiska marknader och bekräftar företagets produktpositionering inom den globala nutraceutical-sektorn. Eevia Health Plc grundades i mars 2017 och fokuserar på att hantera globala hälsoutmaningar med bioaktiva föreningar från förnybara växtmaterial. Företaget tillverkar 100% ekologiskt certifierade växtextrakt, främst från skogar i Finland och Sverige. Dessa säljs B2B som ingredienser till kosttillskott och livsmedelsvarumärken globalt. Eevia utvecklar även högvärdiga livsmedelsingredienser och biomaterial som gynnar människors hälsa. Företaget driver en miljövänlig produktionsanläggning i Finland och noterades på Spotlight Stock Market i Sverige i juni 2021 under kortnamnet EEVIA.

The Extraordinary General Meeting will address several key issues, including the opening and organization of the meeting, confirming its legality, and recording attendance. The agenda includes electing a new Board member, Marinus Blåbjerg Sørensen, to fill a vacancy, with his term lasting until the next Annual General Meeting. The meeting will also confirm a previous decision on Board remuneration, involving shares issued as part of a direct placement. Shareholders have requested changes to the Nomination Board, and proposals for new members will be presented. An updated option program for management will be discussed, with details available to shareholders before May 9, 2025. The Board seeks pre-emptive approval for a private share placement to insiders if external investors are not found. Documents related to the meeting will be available on Eevia Health's website by May 6, 2025. Shareholders must register by May 26, 2025, to participate, with specific instructions for those with nominee-registered shares or shares registered with Euroclear Sweden AB. Proxy representation is allowed, and proxy documents must be submitted before the registration deadline. The meeting will also address other standard procedural matters. Eevia Health, founded in 2017, focuses on producing organic plant extracts for global health challenges and operates a production facility in Finland.

Eevia Board has decided to issue 6,000,000 new warrants (TO2) to Lago Kapital Oy, a Finnish investment firm, as part of a strategy to address shares not subscribed in the last rights issue. The aim is to raise approximately 400,000 euros, with the TO2 warrants being a smaller component of this effort. Orcator Oy, a shareholder of Eevia, will lend 6,000,000 shares to Lago Kapital Oy, and Stein Ulve, CEO of Eevia, owns Orcator Oy. Eevia needs additional working capital for streamlining operations, achieving profitability, and meeting demand. The TO2 warrants offer a cost-effective way to raise future capital. The subscription period for shares via the TO2 warrants is from May 12 to June 9, 2025, with each warrant allowing the purchase of one share at 70% of the average market price during the subscription period, but not less than 0.11 SEK. Unexercised warrants by June 11 will expire, and conditions for accelerated vesting apply in cases of control changes. The TO2 warrants are priced at 0.1 Swedish Øre each. These financial moves aim to capitalize on growth opportunities and support efforts for non-dilutive funding of approximately 550,000 euros. Eevia Health, founded in 2017, produces organic plant extracts for health supplements and operates a green-chemistry facility in Finland. The company is listed on the Spotlight Stock Market in Sweden.

Vitafoods, a key event for the nutraceutical industry, will move from Geneva to Barcelona after 26 years, attracting professionals globally. Eevia Health will introduce a new health ingredient with high bioactive polyphenol concentration, made from Finnish organic berries, and will re-launch another ingredient with a new partner. Eevia Health, founded in 2017, produces organic plant extracts for global dietary supplements and food brands, focusing on gut and kidney health. Their production facility in Finland emphasizes sustainability. Eevia's shares are listed on the Spotlight Stock Market in Sweden.

A Swedish brand owner with a presence in over 50,000 retail outlets across 38 countries placed the largest order for Feno-Myrtillus® 1, a bilberry extract. Deliveries are planned for April and May. Additional orders were received from customers in Finland, the U.S., and a new client in France for various organic extracts. The total new sales order amounts to 130,000 euros. Eevia Health ensures immediate shipments due to adequate stock, supporting cash flow and reducing inventory, in line with its turnaround strategy. The company aims to expand its European and global presence, leveraging a growing customer base. Eevia Health, founded in 2017, produces organically certified plant extracts from Finnish and Swedish forests, focusing on health-related bioactive compounds. It operates a green-chemistry facility in Finland and is listed on the Spotlight Stock Market in Sweden. For more information, contact CEO Stein Ulve or visit their website.